Related Experiment Video
Updated: Sep 24, 2025

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
Cardiovascular morbidity and all-cause mortality in patients with retinal vein occlusion: a Danish nationwide cohort
Katrine Hartmund Frederiksen1,2, Lonny Stokholm2,3, Peter Hartmund Frederiksen2,4
1Department of Ophthalmology, Odense University Hospital, Odense, Denmark katrine.h.frederiksen@rsyd.dk.
Insights
Retinal vein occlusion (RVO) is linked to a 13% increased risk of cardiovascular disease (CVD), particularly after 2011. Mortality risk was not significantly elevated overall, but central RVO showed a slight increase.
Area of Science:
- Ophthalmology
- Cardiology
- Public Health
Background:
- Retinal vein occlusion (RVO) associations with cardiovascular disease (CVD) and mortality require updated evaluation.
- Novel therapeutic options for RVO have influenced patient referral patterns.
- Recent cohort data is needed to assess risks following advancements in RVO treatment.
Purpose of the Study:
- To evaluate the overall and subtype-stratified risk of CVD and all-cause mortality following RVO.
- To assess changes in CVD and mortality risk after the introduction of angiostatic therapy in Denmark in 2011.
- To analyze the impact of RVO on cardiovascular health and survival in a contemporary population.
Main Methods:
- Nationwide, registry-based cohort study from 1998 to 2018 in Denmark.
- Inclusion of 4,194,781 individuals, with 15,665 diagnosed with RVO.
- Hazard ratios (HRs) calculated for overall RVO, branch RVO, and central RVO, with subgroup analysis by diagnosis year.
Main Results:
- RVO was associated with a 13% increased risk of incident CVD (aHR 1.13).
- No significant association was found between RVO and all-cause mortality (aHR 1.00).
- Central RVO showed increased mortality risk (aHR 1.12), and CVD risk was higher post-2011 (aHR 1.24).
Conclusions:
- Patients with RVO face a significantly increased risk of incident CVD.
- The introduction of intravitreal angiostatic treatment in 2011 correlated with altered referral practices and increased CVD risk.
- RVO serves as a potential indicator for heightened cardiovascular risk, necessitating further investigation into management strategies.
Background/Aims:
Associations between retinal vein occlusion (RVO) and subsequent cardiovascular disease (CVD) or mortality have not been evaluated in a recent cohort, after novel therapeutic options have increased referrals for treatment of the condition. We aimed to evaluate overall and subtype-stratified risk of CVD and all-cause mortality following RVO and assess any alterations after the introduction of angiostatic therapy in Denmark in 2011.
Methods:
This nationwide, registry-based cohort study from 1998 to 2018 evaluated 4 194 781 individuals. Hazard ratios (HRs) were reported for RVO as an overall measure and subclassified as branch and central RVO.
Results:
Patients with RVO (n=15 665) were median 71.8 years old at the time of exposure and 50.7% were women. RVO associated with incident CVD (adjusted HR 1.13, 95% CI 1.09 to 1.17) but not mortality (adjusted HR 1.00, 95% CI 0.97 to 1.03). Almost similar risks of CVD were found for patients with branch and central RVO (adjusted HRs 1.14, 95% CI 1.03 to 1.25, and 1.12, 95% CI 1.00 to 1.25, respectively), but only patients with central RVO exhibited increased mortality (adjusted HR 1.12, 95% CI 1.04 to 1.21). Risk of CVD, especially non-ischaemic, was higher for patients diagnosed after 2011 (adjusted HRs 1.24, 95% CI 1.15 to 1.33 vs 1.06, 95% CI 1.01 to 1.12).
Conclusion:
In a cohort of the Danish population aged 40 years or more, patients with RVO had a 13% increased risk of incident CVD compared with unexposed individuals. Risk of CVD was increased after 2011, when intravitreal angiostatic treatment was introduced and referral practices altered.
More Related Videos
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Hypertension III: Clinical Manifestations and Diagnostic Studies

